Phase 2 Study of Anlotinib in Advanced Soft Tissue Sarcoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Anlotinib (Primary)
- Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Acronyms ALTN-STS
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 07 Jun 2016 Interim results (n=166) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 05 Apr 2016 Planned End Date changed from 1 Feb 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
- 07 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.